Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
EntrestoⓇ delivering strong double-digit growth in all geographies
Sales evolution
USD m, % cc
US weekly TRX1
Total prescriptions (000)
110
Ex-US
US
100
+37%
90
1,516
80
200
70
1,125
761
60
50
577
40
30
755
20
548
210
10
0
Q2 2022
Q2 2023
July 2015
June 2023
GROWTH
Entresto®
Strong Q2 momentum
US: sales +38% cc, NBRx +17% vs PY, ~1.3m TRx in Q21
Ex-US: sales +36% cc, continued strong growth in HFrEF
China/Japan: Significant contribution from HTN²
Confidence in future growth
Robust guidelines³ (US/EU)
Expect further penetration in HFrEF
(2/3 eligible patients still on prior SoC)
PARAGLIDE in HFPEF met primary endpoint5
Pediatric approval confirms RDP to Nov 2026 EU4
US IP update
Mylan held to infringe crystalline complex patents;
Novartis disagrees with negative decision by Delaware
Court and will appeal to uphold validity of combination
patent
TRX total prescriptions.
See last page for references. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report.
HFPEF-heart failure with preserved ejection fraction. HFrEF-heart failure with reduced ejection fraction. HF heart failure. HTN hypertension. RDP Regulatory data protection.
SOC
6 Investor Relations | Q2 2023 Results
NBRX-new to brand prescriptions.
standard of care.
✓ NOVARTIS | Reimagining MedicineView entire presentation